DUBLIN – (COMMERCIAL THREAD) – The report “Market Spotlight: Waldenstrom Macroglobulinemia (WM)” has been added to ResearchAndMarkets.com offer.
This Market Spotlight report covers the Waldenstrom Macroglobulinemia (WM) market, including major drugs on the market and under development, likelihood of success, clinical trials, upcoming events, recent events, and analyst opinion. , a 10-year disease incidence forecast and drug-specific revenue. forecasts.
Key points to remember
The publisher estimates that in 2017, there were approximately 5,330 incident cases of Waldenstrom’s macroglobulinemia (WM) in people aged 40 and over worldwide, and predicts that number will increase to 6,920 incident cases of ‘by 2026.
It is estimated that the majority of diagnosed cases worldwide were among men in 2017.
Globally, incident cases of WM are highest among individuals aged 60 to 79. Imbruvica and tirabrutinib, two small molecule tyrosine kinase inhibitors, are the only drugs on the market for WM. These therapies are administered orally.
The majority of industry-sponsored drugs in active clinical development for WM are in Phase II, with only two drugs in Phase III. Developing therapies for WM focus on targets such as B cell lymphoma 2 (Bcl-2) / Bcl-2 family, Bruton’s tyrosine kinase, chemokine receptor 4, lipid rafts, casein kinase 1 epsilon, the PI3K / AKT pathway, p110 delta / PIK3CD and proteasome. These drugs are administered orally, intravenously and subcutaneously.
An awaited CHMP opinion for Brukinsa is the only upcoming high impact drug event in the WM space. The overall probability of approval of a phase I hematologic cancer active is 9.2%, and the average probability of a drug progressing to phase III is 60%. Medicines take an average of 9.4 years from phase I to approval, compared to 9.6 years across the cancer space.
The distribution of clinical trials across Phase I-IV indicates that almost all trials for WM have been in the early and middle stages of development, with 94% of trials in Phase I-II, and only 6% in Phase III -IV.
The United States has a substantial lead in the number of WM clinical trials worldwide. The UK and France lead the main European markets, while China ranks first in Asia.
The activity of clinical trials in the WM space is dominated by completed trials. Takeda has the most completed clinical trials for WM, with 11 trials.
Bristol Myers Squibb, Johnson & Johnson and Takeda are the major industry sponsors with the highest overall number of clinical trials for WM.
Main topics covered:
KEY POINTS TO REMEMBER
BACKGROUND OF THE ILLNESS
Biological therapy or immunotherapy
Stem cell transplant (SCT)
MEDICINES BY PIPELINE
RECENT EVENTS AND ANALYST ADVICE
LOXO-305 for MW (December 5, 2020)
Aliqopa for WM (October 14, 2020)
Brukinsa for WM (December 16, 2019)
Mavorixafor for MW (July 17, 2019)
KEY UPCOMING EVENTS
LIKELIHOOD OF SUCCESS
LANDSCAPE OF CLINICAL TRIALS
Sponsors by status
Sponsors by phase
For more information on this report visit https://www.researchandmarkets.com/r/15fkd